Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty

Launched by ST. ANNE'S UNIVERSITY HOSPITAL BRNO, CZECH REPUBLIC · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the effects of a medication called tranexamic acid (TXA) during elective hip replacement surgery. TXA helps reduce bleeding during and after the surgery, which can lead to fewer blood transfusions and potentially lessen complications like unwanted bone growth in soft tissues, known as heterotopic ossification. By using TXA, the researchers hope to see less blood loss and better recovery for patients undergoing total hip arthroplasty (THA) surgeries.

To participate in this study, you need to be scheduled for an elective hip replacement surgery. Unfortunately, if your surgery is due to a hip injury or trauma, you won’t be eligible. If you join the trial, you can expect to have TXA applied during your surgery, and the researchers will monitor your blood loss, hemoglobin levels, and any other related factors throughout your recovery. This study is important as it could improve patient outcomes and reduce healthcare costs associated with blood transfusions and longer hospital stays.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Elective hip replacement
• Exclusion Criteria:
• • Traumatic hip replacement indication